Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2028

Code: QYRE-Othe-0100

Report

February 2022

109 Pages

QYResearch

Region: Global,

Description

Table of Content

Tables & Figures

FEATURED COMPANIES

Johnson and Johnson

Gilead Sciences Inc

Pacira Pharmaceuticals Inc

Sun Pharmaceuticals

Luye Pharma

SigmaTau Group

FudanZhangjiang

Teva Pharmaceuticals

CSPC

Novartis

Kingond Pharm

Johnson & Johnson

Gilead Sciences

Pacira

Sun Pharmaceutical

Sigma-Tau Group

Fudan-Zhangjiang

Teva Pharmaceutical

Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.

Market Analysis and Insights: Global Hepatocellular Carcinoma Drug Market

Due to the COVID-19 pandemic, the global Hepatocellular Carcinoma Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.

Fully considering the economic change by this health crisis, Chemotherapy accounting for % of the Hepatocellular Carcinoma Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Surgical Resection segment is altered to an % CAGR throughout this forecast period.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Hepatocellular Carcinoma Drug in US$ by following Product Segments.: Chemotherapy, Brachytherapy and Ablation Therapy.

Company profiles are primarily based on public domain information including company

Johnson & Johnson

Gilead Sciences

Pacira

Sun Pharmaceutical

Luye Pharma

Sigma-Tau Group

Fudan-Zhangjiang

Teva Pharmaceutical

CSPC

Novartis

Kingond Pharm

Global Hepatocellular Carcinoma Drug Scope and Segment

Hepatocellular Carcinoma Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Hepatocellular Carcinoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Chemotherapy

Brachytherapy

Ablation Therapy

Segment by Application

Surgical Resection

Liver Transplantation

Ablation

BY COMPANY

Johnson & Johnson

Gilead Sciences

Pacira

Sun Pharmaceutical

Luye Pharma

Sigma-Tau Group

Fudan-Zhangjiang

Teva Pharmaceutical

CSPC

Novartis

Kingond Pharm

BY REGION

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

FEATURED COMPANIES

Johnson and Johnson

Gilead Sciences Inc

Pacira Pharmaceuticals Inc

Sun Pharmaceuticals

Luye Pharma

SigmaTau Group

FudanZhangjiang

Teva Pharmaceuticals

CSPC

Novartis

Kingond Pharm

Johnson & Johnson

Gilead Sciences

Pacira

Sun Pharmaceutical

Sigma-Tau Group

Fudan-Zhangjiang

Teva Pharmaceutical

1 Study Coverage

1.1 Hepatocellular Carcinoma Drug Product Introduction

1.2 Market by Type

1.2.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Chemotherapy

1.2.3 Brachytherapy

1.2.4 Ablation Therapy

1.3 Market by Application

1.3.1 Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Surgical Resection

1.3.3 Liver Transplantation

1.3.4 Ablation

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Hepatocellular Carcinoma Drug Sales Estimates and Forecasts 2017-2028

2.2 Global Hepatocellular Carcinoma Drug Revenue Estimates and Forecasts 2017-2028

2.3 Global Hepatocellular Carcinoma Drug Revenue by Region: 2017 VS 2021 VS 2028

2.4 Global Hepatocellular Carcinoma Drug Sales by Region

2.4.1 Global Hepatocellular Carcinoma Drug Sales by Region (2017-2022)

2.4.2 Global Sales Hepatocellular Carcinoma Drug by Region (2023-2028)

2.5 Global Hepatocellular Carcinoma Drug Revenue by Region

2.5.1 Global Hepatocellular Carcinoma Drug Revenue by Region (2017-2022)

2.5.2 Global Hepatocellular Carcinoma Drug Revenue by Region (2023-2028)

2.6 North America

2.7 Europe

2.8 Asia-Pacific

2.9 Latin America

2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Hepatocellular Carcinoma Drug Sales by Manufacturers

3.1.1 Global Top Hepatocellular Carcinoma Drug Manufacturers by Sales (2017-2022)

3.1.2 Global Hepatocellular Carcinoma Drug Sales Market Share by Manufacturers (2017-2022)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hepatocellular Carcinoma Drug in 2021

3.2 Global Hepatocellular Carcinoma Drug Revenue by Manufacturers

3.2.1 Global Hepatocellular Carcinoma Drug Revenue by Manufacturers (2017-2022)

3.2.2 Global Hepatocellular Carcinoma Drug Revenue Market Share by Manufacturers (2017-2022)

3.2.3 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Drug Revenue in 2021

3.3 Global Hepatocellular Carcinoma Drug Sales Price by Manufacturers (2017-2022)

3.4 Analysis of Competitive Landscape

3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Hepatocellular Carcinoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4.3 Global Hepatocellular Carcinoma Drug Manufacturers Geographical Distribution

3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Hepatocellular Carcinoma Drug Sales by Type

4.1.1 Global Hepatocellular Carcinoma Drug Historical Sales by Type (2017-2022)

4.1.2 Global Hepatocellular Carcinoma Drug Forecasted Sales by Type (2023-2028)

4.1.3 Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

4.2 Global Hepatocellular Carcinoma Drug Revenue by Type

4.2.1 Global Hepatocellular Carcinoma Drug Historical Revenue by Type (2017-2022)

4.2.2 Global Hepatocellular Carcinoma Drug Forecasted Revenue by Type (2023-2028)

4.2.3 Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

4.3 Global Hepatocellular Carcinoma Drug Price by Type

4.3.1 Global Hepatocellular Carcinoma Drug Price by Type (2017-2022)

4.3.2 Global Hepatocellular Carcinoma Drug Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Hepatocellular Carcinoma Drug Sales by Application

5.1.1 Global Hepatocellular Carcinoma Drug Historical Sales by Application (2017-2022)

5.1.2 Global Hepatocellular Carcinoma Drug Forecasted Sales by Application (2023-2028)

5.1.3 Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

5.2 Global Hepatocellular Carcinoma Drug Revenue by Application

5.2.1 Global Hepatocellular Carcinoma Drug Historical Revenue by Application (2017-2022)

5.2.2 Global Hepatocellular Carcinoma Drug Forecasted Revenue by Application (2023-2028)

5.2.3 Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

5.3 Global Hepatocellular Carcinoma Drug Price by Application

5.3.1 Global Hepatocellular Carcinoma Drug Price by Application (2017-2022)

5.3.2 Global Hepatocellular Carcinoma Drug Price Forecast by Application (2023-2028)

6 North America

6.1 North America Hepatocellular Carcinoma Drug Market Size by Type

6.1.1 North America Hepatocellular Carcinoma Drug Sales by Type (2017-2028)

6.1.2 North America Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)

6.2 North America Hepatocellular Carcinoma Drug Market Size by Application

6.2.1 North America Hepatocellular Carcinoma Drug Sales by Application (2017-2028)

6.2.2 North America Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)

6.3 North America Hepatocellular Carcinoma Drug Market Size by Country

6.3.1 North America Hepatocellular Carcinoma Drug Sales by Country (2017-2028)

6.3.2 North America Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)

6.3.3 U.S.

6.3.4 Canada

7 Europe

7.1 Europe Hepatocellular Carcinoma Drug Market Size by Type

7.1.1 Europe Hepatocellular Carcinoma Drug Sales by Type (2017-2028)

7.1.2 Europe Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)

7.2 Europe Hepatocellular Carcinoma Drug Market Size by Application

7.2.1 Europe Hepatocellular Carcinoma Drug Sales by Application (2017-2028)

7.2.2 Europe Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)

7.3 Europe Hepatocellular Carcinoma Drug Market Size by Country

7.3.1 Europe Hepatocellular Carcinoma Drug Sales by Country (2017-2028)

7.3.2 Europe Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)

7.3.3 Germany

7.3.4 France

7.3.5 U.K.

7.3.6 Italy

7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Type

8.1.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2017-2028)

8.1.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)

8.2 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Application

8.2.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2017-2028)

8.2.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)

8.3 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Region

8.3.1 Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2017-2028)

8.3.2 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2017-2028)

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 India

8.3.7 Australia

8.3.8 Taiwan

8.3.9 Indonesia

8.3.10 Thailand

8.3.11 Malaysia

8.3.12 Philippines

9 Latin America

9.1 Latin America Hepatocellular Carcinoma Drug Market Size by Type

9.1.1 Latin America Hepatocellular Carcinoma Drug Sales by Type (2017-2028)

9.1.2 Latin America Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)

9.2 Latin America Hepatocellular Carcinoma Drug Market Size by Application

9.2.1 Latin America Hepatocellular Carcinoma Drug Sales by Application (2017-2028)

9.2.2 Latin America Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)

9.3 Latin America Hepatocellular Carcinoma Drug Market Size by Country

9.3.1 Latin America Hepatocellular Carcinoma Drug Sales by Country (2017-2028)

9.3.2 Latin America Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)

9.3.3 Mexico

9.3.4 Brazil

9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Type

10.1.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2017-2028)

10.1.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Type (2017-2028)

10.2 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Application

10.2.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2017-2028)

10.2.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Application (2017-2028)

10.3 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country

10.3.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2017-2028)

10.3.2 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2017-2028)

10.3.3 Turkey

10.3.4 Saudi Arabia

11 Company Profiles

11.1 Johnson & Johnson

11.1.1 Johnson & Johnson Corporation Information

11.1.2 Johnson & Johnson Overview

11.1.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.1.4 Johnson & Johnson Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Johnson & Johnson Recent Developments

11.2 Gilead Sciences

11.2.1 Gilead Sciences Corporation Information

11.2.2 Gilead Sciences Overview

11.2.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.2.4 Gilead Sciences Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Gilead Sciences Recent Developments

11.3 Pacira

11.3.1 Pacira Corporation Information

11.3.2 Pacira Overview

11.3.3 Pacira Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.3.4 Pacira Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 Pacira Recent Developments

11.4 Sun Pharmaceutical

11.4.1 Sun Pharmaceutical Corporation Information

11.4.2 Sun Pharmaceutical Overview

11.4.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.4.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Sun Pharmaceutical Recent Developments

11.5 Luye Pharma

11.5.1 Luye Pharma Corporation Information

11.5.2 Luye Pharma Overview

11.5.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.5.4 Luye Pharma Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Luye Pharma Recent Developments

11.6 Sigma-Tau Group

11.6.1 Sigma-Tau Group Corporation Information

11.6.2 Sigma-Tau Group Overview

11.6.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.6.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Sigma-Tau Group Recent Developments

11.7 Fudan-Zhangjiang

11.7.1 Fudan-Zhangjiang Corporation Information

11.7.2 Fudan-Zhangjiang Overview

11.7.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.7.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Fudan-Zhangjiang Recent Developments

11.8 Teva Pharmaceutical

11.8.1 Teva Pharmaceutical Corporation Information

11.8.2 Teva Pharmaceutical Overview

11.8.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.8.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 Teva Pharmaceutical Recent Developments

11.9 CSPC

11.9.1 CSPC Corporation Information

11.9.2 CSPC Overview

11.9.3 CSPC Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.9.4 CSPC Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 CSPC Recent Developments

11.10 Novartis

11.10.1 Novartis Corporation Information

11.10.2 Novartis Overview

11.10.3 Novartis Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.10.4 Novartis Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.10.5 Novartis Recent Developments

11.11 Kingond Pharm

11.11.1 Kingond Pharm Corporation Information

11.11.2 Kingond Pharm Overview

11.11.3 Kingond Pharm Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2017-2022)

11.11.4 Kingond Pharm Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

11.11.5 Kingond Pharm Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Hepatocellular Carcinoma Drug Industry Chain Analysis

12.2 Hepatocellular Carcinoma Drug Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Hepatocellular Carcinoma Drug Production Mode & Process

12.4 Hepatocellular Carcinoma Drug Sales and Marketing

12.4.1 Hepatocellular Carcinoma Drug Sales Channels

12.4.2 Hepatocellular Carcinoma Drug Distributors

12.5 Hepatocellular Carcinoma Drug Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Hepatocellular Carcinoma Drug Industry Trends

13.2 Hepatocellular Carcinoma Drug Market Drivers

13.3 Hepatocellular Carcinoma Drug Market Challenges

13.4 Hepatocellular Carcinoma Drug Market Restraints

14 Key Findings in The Global Hepatocellular Carcinoma Drug Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

Johnson and Johnson

Gilead Sciences Inc

Pacira Pharmaceuticals Inc

Sun Pharmaceuticals

Luye Pharma

SigmaTau Group

FudanZhangjiang

Teva Pharmaceuticals

CSPC

Novartis

Kingond Pharm

Johnson & Johnson

Gilead Sciences

Pacira

Sun Pharmaceutical

Sigma-Tau Group

Fudan-Zhangjiang

Teva Pharmaceutical

List of Tables

Table 1. Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)

Table 2. Major Manufacturers of Chemotherapy

Table 3. Major Manufacturers of Brachytherapy

Table 4. Major Manufacturers of Ablation Therapy

Table 5. Global Hepatocellular Carcinoma Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)

Table 6. Global Hepatocellular Carcinoma Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)

Table 7. Global Hepatocellular Carcinoma Drug Sales by Region (2017-2022) & (K Units)

Table 8. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2017-2022)

Table 9. Global Hepatocellular Carcinoma Drug Sales by Region (2023-2028) & (K Units)

Table 10. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2023-2028)

Table 11. Global Hepatocellular Carcinoma Drug Revenue by Region (2017-2022) & (US$ Million)

Table 12. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2017-2022)

Table 13. Global Hepatocellular Carcinoma Drug Revenue by Region (2023-2028) & (US$ Million)

Table 14. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2023-2028)

Table 15. Global Hepatocellular Carcinoma Drug Sales by Manufacturers (2017-2022) & (K Units)

Table 16. Global Hepatocellular Carcinoma Drug Sales Share by Manufacturers (2017-2022)

Table 17. Global Hepatocellular Carcinoma Drug Revenue by Manufacturers (2017-2022) & (US$ Million)

Table 18. Global Hepatocellular Carcinoma Drug Revenue Share by Manufacturers (2017-2022)

Table 19. Hepatocellular Carcinoma Drug Price by Manufacturers (2017-2022) &(USD/Unit)

Table 20. Global Hepatocellular Carcinoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 21. Global Hepatocellular Carcinoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drug as of 2021)

Table 22. Hepatocellular Carcinoma Drug Manufacturing Base Distribution and Headquarters

Table 23. Manufacturers Hepatocellular Carcinoma Drug Product Offered

Table 24. Date of Manufacturers Enter into Hepatocellular Carcinoma Drug Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)

Table 27. Global Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)

Table 28. Global Hepatocellular Carcinoma Drug Sales Share by Type (2017-2022)

Table 29. Global Hepatocellular Carcinoma Drug Sales Share by Type (2023-2028)

Table 30. Global Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)

Table 31. Global Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)

Table 32. Global Hepatocellular Carcinoma Drug Revenue Share by Type (2017-2022)

Table 33. Global Hepatocellular Carcinoma Drug Revenue Share by Type (2023-2028)

Table 34. Hepatocellular Carcinoma Drug Price by Type (2017-2022) & (USD/Unit)

Table 35. Global Hepatocellular Carcinoma Drug Price Forecast by Type (2023-2028) & (USD/Unit)

Table 36. Global Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)

Table 37. Global Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)

Table 38. Global Hepatocellular Carcinoma Drug Sales Share by Application (2017-2022)

Table 39. Global Hepatocellular Carcinoma Drug Sales Share by Application (2023-2028)

Table 40. Global Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)

Table 41. Global Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)

Table 42. Global Hepatocellular Carcinoma Drug Revenue Share by Application (2017-2022)

Table 43. Global Hepatocellular Carcinoma Drug Revenue Share by Application (2023-2028)

Table 44. Hepatocellular Carcinoma Drug Price by Application (2017-2022) & (USD/Unit)

Table 45. Global Hepatocellular Carcinoma Drug Price Forecast by Application (2023-2028) & (USD/Unit)

Table 46. North America Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)

Table 47. North America Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)

Table 48. North America Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)

Table 49. North America Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)

Table 50. North America Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)

Table 51. North America Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)

Table 52. North America Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)

Table 53. North America Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)

Table 54. North America Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)

Table 55. North America Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)

Table 56. North America Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)

Table 57. North America Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)

Table 58. Europe Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)

Table 59. Europe Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)

Table 60. Europe Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)

Table 61. Europe Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)

Table 62. Europe Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)

Table 63. Europe Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)

Table 64. Europe Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)

Table 65. Europe Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)

Table 66. Europe Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)

Table 67. Europe Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)

Table 68. Europe Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)

Table 69. Europe Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)

Table 70. Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)

Table 71. Asia Pacific Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)

Table 72. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)

Table 73. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)

Table 74. Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)

Table 75. Asia Pacific Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)

Table 76. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)

Table 77. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)

Table 78. Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2017-2022) & (K Units)

Table 79. Asia Pacific Hepatocellular Carcinoma Drug Sales by Region (2023-2028) & (K Units)

Table 80. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2017-2022) & (US$ Million)

Table 81. Asia Pacific Hepatocellular Carcinoma Drug Revenue by Region (2023-2028) & (US$ Million)

Table 82. Latin America Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)

Table 83. Latin America Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)

Table 84. Latin America Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)

Table 85. Latin America Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)

Table 86. Latin America Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)

Table 87. Latin America Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)

Table 88. Latin America Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)

Table 89. Latin America Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)

Table 90. Latin America Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)

Table 91. Latin America Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)

Table 92. Latin America Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)

Table 93. Latin America Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)

Table 94. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2017-2022) & (K Units)

Table 95. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2023-2028) & (K Units)

Table 96. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Type (2017-2022) & (US$ Million)

Table 97. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Type (2023-2028) & (US$ Million)

Table 98. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2017-2022) & (K Units)

Table 99. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2023-2028) & (K Units)

Table 100. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Application (2017-2022) & (US$ Million)

Table 101. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Application (2023-2028) & (US$ Million)

Table 102. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2017-2022) & (K Units)

Table 103. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2023-2028) & (K Units)

Table 104. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2017-2022) & (US$ Million)

Table 105. Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2023-2028) & (US$ Million)

Table 106. Johnson & Johnson Corporation Information

Table 107. Johnson & Johnson Description and Major Businesses

Table 108. Johnson & Johnson Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 109. Johnson & Johnson Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 110. Johnson & Johnson Recent Developments

Table 111. Gilead Sciences Corporation Information

Table 112. Gilead Sciences Description and Major Businesses

Table 113. Gilead Sciences Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 114. Gilead Sciences Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 115. Gilead Sciences Recent Developments

Table 116. Pacira Corporation Information

Table 117. Pacira Description and Major Businesses

Table 118. Pacira Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 119. Pacira Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 120. Pacira Recent Developments

Table 121. Sun Pharmaceutical Corporation Information

Table 122. Sun Pharmaceutical Description and Major Businesses

Table 123. Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 124. Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 125. Sun Pharmaceutical Recent Developments

Table 126. Luye Pharma Corporation Information

Table 127. Luye Pharma Description and Major Businesses

Table 128. Luye Pharma Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 129. Luye Pharma Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 130. Luye Pharma Recent Developments

Table 131. Sigma-Tau Group Corporation Information

Table 132. Sigma-Tau Group Description and Major Businesses

Table 133. Sigma-Tau Group Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 134. Sigma-Tau Group Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 135. Sigma-Tau Group Recent Developments

Table 136. Fudan-Zhangjiang Corporation Information

Table 137. Fudan-Zhangjiang Description and Major Businesses

Table 138. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 139. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 140. Fudan-Zhangjiang Recent Developments

Table 141. Teva Pharmaceutical Corporation Information

Table 142. Teva Pharmaceutical Description and Major Businesses

Table 143. Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 144. Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 145. Teva Pharmaceutical Recent Developments

Table 146. CSPC Corporation Information

Table 147. CSPC Description and Major Businesses

Table 148. CSPC Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 149. CSPC Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 150. CSPC Recent Developments

Table 151. Novartis Corporation Information

Table 152. Novartis Description and Major Businesses

Table 153. Novartis Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 154. Novartis Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 155. Novartis Recent Developments

Table 156. Kingond Pharm Corporation Information

Table 157. Kingond Pharm Description and Major Businesses

Table 158. Kingond Pharm Hepatocellular Carcinoma Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 159. Kingond Pharm Hepatocellular Carcinoma Drug Product Model Numbers, Pictures, Descriptions and Specifications

Table 160. Kingond Pharm Recent Developments

Table 161. Key Raw Materials Lists

Table 162. Raw Materials Key Suppliers Lists

Table 163. Hepatocellular Carcinoma Drug Distributors List

Table 164. Hepatocellular Carcinoma Drug Customers List

Table 165. Hepatocellular Carcinoma Drug Market Trends

Table 166. Hepatocellular Carcinoma Drug Market Drivers

Table 167. Hepatocellular Carcinoma Drug Market Challenges

Table 168. Hepatocellular Carcinoma Drug Market Restraints

Table 169. Research Programs/Design for This Report

Table 170. Key Data Information from Secondary Sources

Table 171. Key Data Information from Primary Sources

List of Figures

Figure 1. Hepatocellular Carcinoma Drug Product Picture

Figure 3. Global Hepatocellular Carcinoma Drug Market Share by Type in 2021 & 2028

Figure 3. Chemotherapy Product Picture

Figure 4. Brachytherapy Product Picture

Figure 5. Ablation Therapy Product Picture

Figure 6. Global Hepatocellular Carcinoma Drug Market Share by Application in 2021 & 2028

Figure 7. Surgical Resection

Figure 8. Liver Transplantation

Figure 9. Ablation

Figure 10. Hepatocellular Carcinoma Drug Report Years Considered

Figure 11. Global Hepatocellular Carcinoma Drug Sales 2017-2028 (K Units)

Figure 12. Global Hepatocellular Carcinoma Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028

Figure 13. Global Hepatocellular Carcinoma Drug Revenue 2017-2028 (US$ Million)

Figure 14. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028

Figure 15. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2017-2022)

Figure 16. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2023-2028)

Figure 17. North America Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)

Figure 18. North America Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)

Figure 19. Europe Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)

Figure 20. Europe Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)

Figure 21. Asia-Pacific Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)

Figure 22. Asia-Pacific Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)

Figure 23. Latin America Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)

Figure 24. Latin America Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)

Figure 25. Middle East & Africa Hepatocellular Carcinoma Drug Sales YoY (2017-2028) & (K Units)

Figure 26. Middle East & Africa Hepatocellular Carcinoma Drug Revenue YoY (2017-2028) & (US$ Million)

Figure 27. The Hepatocellular Carcinoma Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021

Figure 28. The Top 5 and 10 Largest Manufacturers of Hepatocellular Carcinoma Drug in the World: Market Share by Hepatocellular Carcinoma Drug Revenue in 2021

Figure 29. Global Hepatocellular Carcinoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021

Figure 30. Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

Figure 31. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

Figure 32. Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

Figure 33. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

Figure 34. North America Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

Figure 35. North America Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

Figure 36. North America Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

Figure 37. North America Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

Figure 38. North America Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)

Figure 39. North America Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)

Figure 40. U.S. Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 41. Canada Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 42. Europe Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

Figure 43. Europe Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

Figure 44. Europe Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

Figure 45. Europe Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

Figure 46. Europe Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)

Figure 47. Europe Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)

Figure 48. Germany Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 49. France Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 50. U.K. Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 51. Italy Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 52. Russia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 53. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

Figure 54. Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

Figure 55. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

Figure 56. Asia Pacific Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

Figure 57. Asia Pacific Hepatocellular Carcinoma Drug Sales Share by Region (2017-2028)

Figure 58. Asia Pacific Hepatocellular Carcinoma Drug Revenue Share by Region (2017-2028)

Figure 59. China Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 60. Japan Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 61. South Korea Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 62. India Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 63. Australia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 64. Taiwan Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 65. Indonesia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 66. Thailand Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 67. Malaysia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 68. Philippines Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 69. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

Figure 70. Latin America Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

Figure 71. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

Figure 72. Latin America Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

Figure 73. Latin America Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)

Figure 74. Latin America Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)

Figure 75. Mexico Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 76. Brazil Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 77. Argentina Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 78. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Type (2017-2028)

Figure 79. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Type (2017-2028)

Figure 80. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Application (2017-2028)

Figure 81. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Market Share by Application (2017-2028)

Figure 82. Middle East and Africa Hepatocellular Carcinoma Drug Sales Share by Country (2017-2028)

Figure 83. Middle East and Africa Hepatocellular Carcinoma Drug Revenue Share by Country (2017-2028)

Figure 84. Turkey Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 85. Saudi Arabia Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 86. U.A.E Hepatocellular Carcinoma Drug Revenue (2017-2028) & (US$ Million)

Figure 87. Hepatocellular Carcinoma Drug Value Chain

Figure 88. Hepatocellular Carcinoma Drug Production Process

Figure 89. Channels of Distribution

Figure 90. Distributors Profiles

Figure 91. Bottom-up and Top-down Approaches for This Report

Figure 92. Data Triangulation

Figure 93. Key Executives Interviewed

REPORTS VIEWED RECENTLY

Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2028

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows multiple user to access the PDF.

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (10% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2028

Published Date: February 2022

Report Code: QYRE-Othe-0100

Global Hepatocellular Carcinoma Drug Market Insights, Forecast to 2028

Code: QYRE-Othe-0100

Report

February 2022

109 Pages

QYResearch

Region: Global,

FEATURED COMPANIES

Segment by Type

Segment by Application

BY COMPANY

BY REGION

FEATURED COMPANIES

FEATURED COMPANIES

REPORTS VIEWED RECENTLY

SELECT A FORMAT

Single User

Electronic (PDF)

$4900

Multi User

Electronic (PDF)

$7350

Enterprise User

Electronic (PDF)

$9800

HAVE A QUERY?

OUR CUSTOMER

RELATED REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-9Z7409

Wed May 18 00:00:00 UTC 2022

Add to Cart

120 Pages

Type: Report

Code: ALLI-Manu-4E69

Sat May 14 07:38:06 UTC 2022

Add to Cart

120 Pages

Type: Report

Code: QYRE-Auto-0T7466

Fri May 13 00:00:00 UTC 2022

Add to Cart

120 Pages

Type: Report

Code: QYRE-Auto-28A10066

Tue May 03 00:00:00 UTC 2022

Add to Cart

Support Contacts

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

POLICIES

THE COMPANY

CUSTOMER SUPPORT

OUR PRODUCTS

POLICES

Copyright © 2018 Valuates.com. All Rights Reserved.

Sitemap - Privacy Policy - Terms & Conditions